News

AbstractAntibodies directed at the amyloid-β peptide offer the prospect of disease-modifying therapy for early-stage Alzheimer disease but also carry the risk of…

Carlisle, PA…  Now in its third decade of doing good for those impacted by Amyloidosis, the Chip Miller Amyloidosis Foundation (CMAF) works year-round to raise…

NORD and Yale Genetics are hosting a Rare Disease Day celebration at the Yale Peabody Museum! Join us for a night of community building & connection. Attendees…

Join NORD’s Pennsylvania Rare Action Network for a virtual Rare Disease Day celebration on Friday, February 20 from 12pm to 1:10pm ET

Isatuximab monotherapy resulted in promising hematologic response rates with a good safety profile among patients with relapsed/refractory (R/R) light chain (AL)…

Light-chain (AL) amyloidosis is a rare systemic disorder characterized by the deposition of misfolded protein aggregates into various organs such as the heart,…

In a letter published in HemaSphere, Claudia Bellofiore, MD, of the University of Pavia in Italy, and colleagues highlighted the need to expand clinical trial…